Jun 29, 2022

News provided by Share this article Share this article The global point-of-care glucose testing market size is expected to reach USD 4.5 billion by 2030, growing at a CAGR of 4.1% over the forecast period. An increase in the demand for Point-of-Care Testing (POCT) has been witnessed in recent years. As compared to the conventional laboratory testing performed in central lab settings, glucose POCT aids in performing effective diagnosis at the patient's bedside. The easy and convenient operation of POCT has largely favored the growing usage of glucose meters across medical settings. The demand for performing bedside monitoring of blood sugar levels efficiently in a capillary blood sample and the need to ensure better management of carbohydrate metabolism have propelled the companies to launch innovative glucose meters in the market. Point-of-Care Glucose Testing Market Report Highlights Accu-Chek Inform II accounted for the largest revenue share in 2021 and is anticipated to maintain this trend throughout the forecast period. Bayer Contour blood glucose monitoring system is set to grow at a CAGR of 6.1% from 2022 to 2030. North America is the leading regional market due to the higher penetration of novel diagnostic techniques. Asia Pacific is estimated to register the fastest CAGR owing to the ever-increasing prevalence of diabetes and numerous untapped growth opportunities in diagnostics. Moreover, a robust network of local manufacturers has significantly contributed to the revenue generated in this region. Key Topics Covered: Chapter 2. Executive Summary 3.1. Market Lineage Outlook